Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to F/TAF from ABC/3TC in Virologically Suppressed HIV-1 Adults
NCT02469246Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Jun 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02469246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469246.